GlassScriptPhysician profile
Robert Wesley Rakowczyk
NPI 1700236486
$1,681.92
in general payments reported to CMS, 2019-2025
19 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $48.53 · 2021: $37.34 · 2022: $172 · 2023: $505 · 2024: $205 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $177.29 | 2021-2023 | Proclaim |
| Amgen INC. | $135.95 | 2025 | Repatha |
| Regeneron Healthcare Solutions, INC. | $131.40 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.25 | 2025 | Caplyta |
| Lilly USA, LLC | $127.32 | 2023-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $121.65 | 2019 | |
| Novo Nordisk INC | $121.22 | 2023 | Wegovy |
| Corcept Therapeutics | $114.14 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $113.09 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $88.05 | 2023 | Quviviq |
| Pfizer INC. | $78.21 | 2025 | |
| Procept Biorobotics Corporation | $69.04 | 2025 | |
| Inspire Medical Systems, INC. | $61.71 | 2024 | Inspire |
| Si-Bone, INC. | $59.51 | 2022 | |
| Medtronic Vascular, INC. | $48.53 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.79 | 2023 | Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $30.18 | 2024 | |
| Medtronic, INC. | $20.96 | 2023 | Vanta Adaptivestim |
| Sanofi Pasteur INC. | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rakowczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.